论文部分内容阅读
为了寻求能够预示克罗米芬发生排卵的剂量,本文对158例无排卵妇女作了前瞻性观查。10年来我们使用一个特殊的递增的克罗米芬活疗方案,虽然排卵率及妊娠率高,但未能预示能引起排卵的剂量,因此开始一个前瞻性的研究,观查无论是实验室还是临床的指标或是二者结合能预示克罗米芬发生排卵的剂量。1979年Shepard等发表一篇对56例妇女使用克罗米芬治疗的回顾性分析,指出高体重妇女需要较大剂量克罗米芬。其原因是否因为肥胖常合并激素的异常,如性激素结合力下降,血浆雌二醇(E_2)浓度增高,或是肥胖与雄激素增高相伴存,后者与卵
In an attempt to find a dose that would predict the onset of ovulation in clomiphene, we prospectively evaluated 158 anovulatory women. For 10 years we have used a special escalation clomiphene-based regimen that, although high in ovulation and pregnancy rates, failed to predict the dose that would trigger ovulation and therefore started a prospective study to investigate whether clofibrate, both in the laboratory and in the clinic Indicators or a combination of the two predict the dose of clomiphene for ovulation. In 1979, Shepard et al. Published a retrospective analysis of the use of clomiphene in 56 women, noting that high-weight women needed greater doses of clomiphene. The reason is because obesity often associated with abnormal hormones, such as decreased sex hormone binding, plasma estradiol (E 2) concentration, or obesity and androgen associated with the increase, the latter with the egg